Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JNJ-64565111 in Renal Impairment
NCT03546205Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Dec 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of efinopegdutide in obesity and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Serum Analyte Concentration at 984 hours, Area Under the Serum Analyte Concentration-Time Curve from Time Zero to Last Measurable Concentration at 984 hours and 1 more. Started Jun 2018; status: completed.
02
Drugs
efinopegdutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03546205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546205.